Jetcraft First to Offer Microshield 360 Antimicrobial Treatment by F/LIST
20.7.2020 11:00:00 EEST | Business Wire | Press release
Jetcraft, the world leader in business jet sales and acquisitions, is the launch customer for interiors specialist F/LIST’s Microshield 360 treatment program, which protects against SARS-CoV-2* and other pathogens that may otherwise live on cabin surfaces.
Additionally, Jetcraft is the first aircraft dealer using MicroShield 360. The coating system is available for all in-service aircraft purchased through the company, and will be applied to all eligible aircraft within Jetcraft’s owned inventory, beginning July 14.
Chad Anderson, president at Jetcraft, says: “MicroShield 360 is one of many ways we are expanding our offering to meet clients’ needs during Covid-19. We are pleased to be the first aircraft dealer implementing the treatment, so buyers can be confident their health is protected when purchasing directly from Jetcraft.
“Our first two jets, a Bombardier Challenger 604 and Global 5000, were treated by F/LIST on July 14. I was highly impressed by the speed of the application, which only took two hours from start to finish for a whole year of protection.”
MicroShield 360 is an antimicrobial coating system which is colorless, odorless and safe for all aircraft interiors. Owners can be reassured that it is eco-friendly, non-toxic and hypoallergenic, and won’t cause any deterioration to their aircraft cabin.
The interior application takes place in two parts: an initial disinfectant to sterilize the cabin, followed by the application of MicroShield 360, which forms a barrier of nanoscopic spikes. The spikes physically destroy germs by piercing the cell membranes, preventing them from adhering to and contaminating a surface.
An electrostatic sprayer is used to apply MicroShield 360, generating a molecular bond with the cabin surface which is equal to 40x the pull of gravity. As a result, the system is extremely abrasion resistant. Combined with regular cleaning, the treatment will ensure all surfaces are effectively self-disinfecting for 12+ months.
Sean Johnson, CEO, F/LIST Canada, adds: “In the present climate, it pays to be fastidious about your health and the cleanliness of your environment, particularly whilst traveling. With F/List partnering with Jetcraft we can bring MicroShield 360 directly to new aircraft owners, underlining how safe, controlled and comfortable travel can be when flying privately. F/List has long been known for innovative technologies that upgrade the cabin experience, and MicroShield 360 falls perfectly into that category.”
All Microshield 360 treatments are subject to Jetcraft approval. Some exclusions apply.
*SARS-CoV-2 is the virus that causes Covid-19.
ENDS
About Jetcraft
Jetcraft is the leader in international aircraft sales, marketing and ownership strategies, managing and maintaining over 20 regional offices globally. The company’s unparalleled success over more than 55 years in business aviation has earned it a world-class reputation, along with an exceptional customer base, a wide network of connections and one of the largest inventories within the industry.
For more information, please visit www.jetcraft.com
About F/LIST
F/LIST is a worldwide provider of interiors for business jets, yachts and residences, and engages more than 900 employees at eight locations in Europe, the Middle East and the Americas. Passion, reliability and a visionary spirit determine every step of this Austrian family-run business.
For more information, please visit https://f-list.at/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005038/en/
Contact information
8020 Communications.
Michaela Wilkins
Email: jetcraft@8020comms.com
Telephone: +44 (0)1483 447380
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom